Treatment∆
| GSH-Pxa
| CATb
| SODc
|
---|
Normal control | 1029.23±79.08 | 30.28±2.91 | 103.07±5.52 |
Cy(100 mg/kg) | 566.53±26.56##
| 17.23±1.48##
| 54.66±9.61##
|
ZYQL-A(100 mg/kg) | 1097.86±96.38 | 33.87±1.05 | 106.14±14.07 |
ZYQL-B(200 mg/kg) | 1181.81±44.51##
| 45.02±6.00##
| 131.75±37.18##
|
ZYQL-C(400 mg/kg) | 1167.57±39.34##
| 42.96±6.94##
| 140.00±20.25##
|
ZYQL-A(100 mg/kg)+Cy | 646.71±42.88*
| 19.85±1.65**
| 79.16±12.69**
|
ZYQL-B(200 mg/kg)+Cy | 724.57±56.51**
| 23.57±0.66**
| 87.46±9.54**
|
ZYQL-C(400 mg/kg)+Cy | 722.08±112.92**
| 20.24±1.30**
| 81.66±10.26**
|
- Data is expressed as the mean±SD (n = 10).
-
a μmol/g protein.
-
b U/mg protein.
-
c U/mg protein.
-
## Significant difference at p<0.01 levels compared with normal control group.
-
** Significant difference at p<0.01 levels compared with Cy-treated group.
-
* Significant difference at p<0.05 levels compared with Cy-treated group.
-
∆ Significant difference at p<0.05 (fCAT = 9.476, fSOD = 2.613) levels compared between cyclophosphamide-untreated groups and cyclophosphamide-treated groups (two-way ANOVA followed by LSD’s test).